上皮成長因子受容体により活性化される新規プロドラッグの開発と肺癌治療への応用

• Project/Area Number: 21K15234
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47010:Pharmaceutical chemistry and drug development sciences-related
• Research Institution: Showa Pharmaceutical University
• Principal Investigator: 小島 拓之 昭和薬科大学, 薬学部, 助教 (20824949)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Project Status: Adopted (Fiscal Year 2021)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)